- Home
- Publications
- Publication Search
- Publication Details
Title
Observational data: Understanding the real MS world
Authors
Keywords
-
Journal
Multiple Sclerosis Journal
Volume 22, Issue 13, Pages 1642-1648
Publisher
SAGE Publications
Online
2016-06-07
DOI
10.1177/1352458516653667
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis
- (2016) T. Spelman et al. EUROPEAN JOURNAL OF NEUROLOGY
- Reporting treatment outcomes in observational data: A fine balance
- (2016) Tomas Kalincik et al. Multiple Sclerosis Journal
- Contribution of different relapse phenotypes to disability in multiple sclerosis
- (2016) Tamasine Stewart et al. Multiple Sclerosis Journal
- A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod
- (2016) Nils Koch-Henriksen et al. Multiple Sclerosis Journal
- Comparative efficacy of fingolimod vs natalizumab
- (2016) Laetitia Barbin et al. NEUROLOGY
- Reporting treatment outcomes in observational data: A fine balance
- (2016) Tomas Kalincik et al. Multiple Sclerosis Journal
- Contribution of different relapse phenotypes to disability in multiple sclerosis
- (2016) Tamasine Stewart et al. Multiple Sclerosis Journal
- A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod
- (2016) Nils Koch-Henriksen et al. Multiple Sclerosis Journal
- Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis
- (2015) Tomas Kalincik et al. ANNALS OF NEUROLOGY
- Defining reliable disability outcomes in multiple sclerosis
- (2015) Tomas Kalincik et al. BRAIN
- Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
- (2015) Pietro Iaffaldano et al. BRAIN
- Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
- (2015) Barbara H. Johnson et al. CNS DRUGS
- Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
- (2015) Stefan Braune et al. JOURNAL OF NEUROLOGY
- Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
- (2015) Anna He et al. JAMA Neurology
- Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort
- (2014) Mohammad Ehsanul Karim et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis
- (2014) Niklas Bergvall et al. CURRENT MEDICAL RESEARCH AND OPINION
- Influence of treatments in multiple sclerosis disability: A cohort study
- (2014) Eleonora Cocco et al. Multiple Sclerosis Journal
- Can we measure long-term treatment effects in multiple sclerosis?
- (2014) Maria Pia Sormani et al. Nature Reviews Neurology
- Fingolimod after natalizumab and the risk of short-term relapse
- (2014) V. G. Jokubaitis et al. NEUROLOGY
- Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
- (2013) Stefan Braune et al. JOURNAL OF NEUROLOGY
- Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis
- (2012) Afsaneh Shirani et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis
- (2011) Luca Prosperini et al. Multiple Sclerosis Journal
- Methodologies for data quality assessment and improvement
- (2009) Carlo Batini et al. ACM COMPUTING SURVEYS
- Real-life impact of early interferonβ therapy in relapsing multiple sclerosis
- (2009) M. Trojano et al. ANNALS OF NEUROLOGY
- Will Rogers phenomenon in multiple sclerosis
- (2008) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started